DR. DAVID E MARTIN, MD
Radiology at Shaffer St, Kalamazoo, MI

License number

Michigan 4301044228

Professional information

Dr. David E Martin, Kalamazoo MI - MD (Doctor of Medicine)

Specialties:

Cardiac Surgery

Address:

Borgess Cardiothoracic Surgery
1722 Shaffer St SUITE 2, Kalamazoo 49048
(269) 343-1555 (Phone), (269) 343-3207 (Fax)

Procedures:

Cardiac Surgical Procedures, Coronary Angioplasty, Atherectomy and Stent, Heart Surgery

Conditions:

Cardiovascular Disorders, Congestive Heart Failure, Heart Attack (Acute Myocardial Infarction)

Certifications:

General Surgery, 1986, Thoracic Cardiovascular Surgery, 1989

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

Borgess Cardiothoracic Surgery
1722 Shaffer St SUITE 2, Kalamazoo 49048
Borgess Medical Center
1521 Gull Rd, Kalamazoo 49048

Philosophy:

Patients by physician referral only. Borgess Cardiothoracic Surgery is a part of Borgess Heart Institute, offering outstanding contributions toward improving cardiac patient outcomes throughout southwest Michigan. We strive to provide high-quality care with personal attention to your questions and concerns.

Education:

Medical School
Wayne State University School Of Medicine
Wayne State University Affiliated Hospitals

Leed Ap Bd+C, Project Director, Senior Associate At Kingscott

Position:

Project Director, Senior Associate at Kingscott

Location:

Kalamazoo, Michigan Area

Industry:

Architecture & Planning

Work:

Kingscott - Kalamazoo, Michigan since Sep 2000 - Project Director, Senior Associate

Education:

Ferris State University 1980 - 1983
Kellogg Community College

Skills:

LEED, Sustainable Design, Construction Documents, Interior Design, Healthcare, Architectural Design, Engineering, Contract Negotiation, Renovation, K-12, Revit, LEED AP, Architecture, Submittals

Interests:

Musician and Guitar Player, Loves music, hunting and fishing. Skilled with all aspects of technology equipment and software.

David E Martin, Kalamazoo MI

Specialties:

Thoracic Surgery, Cardiothoracic Vascular Surgery, Surgery, Vascular Surgery

Work:

Borgess Cardiothoracic Surgery
1722 Shaffer St, Kalamazoo, MI 49048 Cardiac Surgery Institute
1030 Harrington St, Mount Clemens, MI 48043 Cardiac Surgery Institute
22151 Moross Rd, Grosse Pointe, MI 48236 Cardiac Surgery Institute
22250 Providence Dr, Southfield, MI 48075 Cardiac Surgery Institute
18181 Oakwood Blvd, Dearborn, MI 48124 Sinai-Grace Hospital
6767 W Outer Dr, Detroit, MI 48235

Education:

Wayne State University (1980)

David E Martin, Kalamazoo MI

Specialties:

Cardiothoracic Surgeon

Address:

1722 Shaffer St, Kalamazoo, MI 49048

Education:

Wayne State University, School of Medicine - Doctor of Medicine
Detroit Receiving Hospital-University Health Center - Fellowship - Thoracic Surgery
Detroit Receiving Hospital-University Health Center - Residency - Thoracic Surgery
Detroit Receiving Hospital-University Health Center - Residency - Surgery

Board certifications:

American Board of Thoracic Surgery Certification in Thoracic and Cardiac Surgery (Thoracic Surgery)

Composition Of Matter And Process

US Patent:

4169888, Oct 2, 1979

Filed:

Oct 17, 1977

Appl. No.:

5/842914

Inventors:

Ladislav J. Hanka - Kalamazoo MI
David G. Martin - Kalamazoo MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C12D 914, C07G 1100

US Classification:

424121

Abstract:

Novel antibiotic CC-1065 producible in a fermentation under controlled conditions using the new microorganism Streptomyces zelensis, NRRL 11,183. This antibiotic is active against Gram-positive bacteria, for example, Staphylococcus aureus, Bacillus subtilis, Streptococcus pyogenes, Sarcina lutea, and Streptococcus faecalis. It is also active against Gram-negative bacteria, for example, Escherichia coli, Proteus vulgaris, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Salmonella pullorum. Thus, antibiotic CC-1065 can be used in various environments to eradicate or control such bacteria.

.Alpha.s, 4S, 5R .Alpha.-Amino-3-Chloro-4-Hydroxy-2-Isoxazoline-5-Acetic Acid

US Patent:

3944562, Mar 16, 1976

Filed:

Apr 17, 1974

Appl. No.:

5/461635

Inventors:

David G. Martin - Kalamazoo MI
Ladislav J. Hanka - Kalamazoo MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

c07D26104

US Classification:

260307F

Abstract:

Antibiotic U-43,795, producible by culturing Streptomyces sviceus in an aqueous nutrient medium has the following structure ##EQU1## The absolute configuration of U-43,795 was determined to be. alpha. S, 4S, 5R. alpha. -amino-3-chloro-4-hydroxy-2-isoxazoline-5-acetic acid. It is an amphoteric compound and can exist in different ionic forms according to the pH of the environment. At low pH, U-43,795 exists in the acid-addition salt form, at a higher pH in a zwitterion form, and at still higher pH in a metal salt form. U-43,795 inhibits the growth of Bacillus subtilis and Sarcina lutea, and can be used to inhibit such microorganisms in various environments.

Antibiotic Pentalenolactone Derivative

US Patent:

4150036, Apr 17, 1979

Filed:

Jun 15, 1978

Appl. No.:

5/915615

Inventors:

David G. Martin - Kalamazoo MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C07D31194

US Classification:

26034321

Abstract:

Novel antibiotic U-36,699 which has been identified as the. alpha. -methylene derivative of pentalenolactone. Antibiotic U-36,699 has the following structural formula ##STR1## This antibiotic is produced in a chemical process using pentalenolactone (also known as antibiotic P. A. 132), as the starting material. Antibiotic U-36,699 is active against Staphylococus aureua, Sarcina lutea, Mycobacterium phlei, Mycobacterium avium, Saccharomyces cerevisiae, and Penicillium oxalicum. Thus, antibiotic U-36,699 can be used in various environments to eradicate or control such fungi and bacteria. Further, antibiotic U-36,699 inhibits P 388 leukemia cells in laboratory mice. Thus, this antibiotic can be used to treat laboratory mice harboring P 388 leukemia cells.

Purification Of At-125

US Patent:

4188324, Feb 12, 1980

Filed:

Nov 13, 1978

Appl. No.:

5/960217

Inventors:

David G. Martin - Kalamazoo MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C07D26104

US Classification:

548240

Abstract:

Process for the purification of L-(. alpha. s,5s)-. alpha. -amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Also provided are AT-125 analogs prepared in the process.

Purification Of At-125

US Patent:

4232164, Nov 4, 1980

Filed:

Jun 23, 1978

Appl. No.:

5/918569

Inventors:

David G. Martin - Kalamazoo MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C07D26104

US Classification:

548240

Abstract:

Process for the purification of L-(. alpha. S,5S)-. alpha. -amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125). Also provided are AT-125 analogs prepared in the process.

Cc-1065 Analogs

US Patent:

5332837, Jul 26, 1994

Filed:

Jan 22, 1993

Appl. No.:

8/010526

Inventors:

Robert C. Kelly - Augusta MI
David G. Martin - Kalamazoo MI
Paul A. Aristoff - Portage MI

Assignee:

The Upjohn Company - Kalamazoo MI

International Classification:

C07D48704, C07D48708, A61K 3140

US Classification:

548433

Abstract:

This invention concerns 2-acyl-4,5,8,8a-tetrahydro-4-oxycyclopropan[c]pyrrol(3,2-e) indole derivatives of Formula I': ##STR1## the compounds of Formula I' are useful as uv light absorber substances, as chemical intermediates and as prodrugs of known spirocyclopropylpyrroloindole CC-1065 analogs. Representative Formula I' compounds have been shown to possess useful ranges of antitumor activity in standard laboratory animal tests.